China Botanic Pharmaceutical Inc. ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, has announced that the State Intellectual Property Office of the People's Republic of China has granted China patent No. ZL200710301682X to China Botanic for its proprietary process to separate and extract effective parts of Siberian Ginseng (Acanthopanax).
China Botanic Pharmaceutical Inc. ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, has announced that the State Intellectual Property Office of the People's Republic of China has granted China patent No. ZL200710301682X to China Botanic for its proprietary process to separate and extract effective parts of Siberian Ginseng (Acanthopanax).
The patent will also protect the resulting Siberian Ginseng extracts and their applications and will provide market exclusivity for a period of 20 years.
The patent for "Extraction of Effective Parts of Siberian Ginseng and their Preparation and Application" is the catalyst that will continue to drive the development of the Company's innovative Acanthopanax series.
Among recent successes using these processes are Lyophilized Syringin Powder and Total Flavonoids capsules. These medicines are powerful new tools in combating depression and senile dementia and have been recognized as "class one new drugs" and "innovative drugs" by the State Food and Drug Administration of China. The patent covers a wide variety of possible Siberian Ginseng extraction methods and applications, creating a high barrier to entry for competitors seeking to develop similar Siberian Ginseng products, and, as a result, it confers significant independent intellectual property rights on the Company.
"It is highly gratifying to receive patent protection for our advancements in the treatment of depression using all-natural Siberian Ginseng extracts. With our exclusive access to a large proportion of the Siberian Ginseng resources, and now this important protection for the extracts we obtain from the plant, our methods of preparation and their applications, we feel this is a major step forward. The issuance of this patent will enhance the commercial potential of our Siberian Ginseng applications in China, one of the largest markets for depression therapies, and further strengthen our leading market position," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic.
"We believe Syringin Powder will be our most powerful depression fighter to date and we continue to discover additional properties of Siberian Ginseng every day. We are excited about future revenue growth and opportunities created as a result of the patent and the high-quality efforts of our R&D program, which continues to earn us attractive returns. We also plan to apply for a series of domestic and overseas patents for each Siberian Ginseng extract that has deep development value and eventually form a patent protection network for our core technology," concluded Mr. Li.
Source: China Botanic Pharmaceutical Inc.